MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

Viralgen and Axovia Therapeutics are partnering to develop and manufacture a gene therapy for the treatment of retinal dystrophy in patients with Bardet-Biedl Syndrome (BBS) caused by biallelic ...

Viralgen and Axovia Therapeutics are set to form a partnership to progress the development and manufacturing of an adeno-associated virus vector serotype 9 (AAV9)-based gene therapy for retinal ...

Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...

BCD是一种由CYP4V2基因突变引起的罕见的遗传性眼病，将导致患者视力逐渐减退，最终可能引起失明。目前，该疾病没有任何有效的治疗方法，患者们只能面临自身视力逐渐消失、丧失生活自理能力的残酷现实。

Life-changing gene therapies for hemophilia have become available, yet many patients and providers have not yet rushed to try ...

National Institute of Standards and Technology scientists looked at multiple techniques used to measure the modified viruses ...

Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.

Common measurements for modified adeno-associated viruses (AAVs), a gene therapy delivery method, showed substantial ...

The therapy is a critical treatment option for various life-threatening disease. Earlier, GST on gene therapy was set at 12 ...

MeiraGTx's financials show $125 million in cash, but additional funding will be needed within the next 12 months. Click for ...

The study found that the number of advanced therapy Phase I trials in the UK nearly doubled since the same time in 2023.